Inner retinal layer thickness reflects plasma biomarkers in preclinical Alzheimer’s disease - Scorecard - MDSpire

Inner retinal layer thickness reflects plasma biomarkers in preclinical Alzheimer’s disease

  • By

  • Jane W. Chan

  • Ziyuan Wang

  • Emily Xu

  • Ibrahim Abboud

  • Aya Alhasany

  • Sophia Xu

  • Xiaomeng Wu

  • Natalie Astraea

  • Fei Jiang

  • Zhihong Jewel Hu

  • May 18, 2026

  • 0 min

Share

Clinical Scorecard: Retinal Layer Thickness Correlates with Plasma Biomarkers in Individuals at Risk for Alzheimer’s Disease

At a Glance

CategoryDetail
ConditionAlzheimer’s Disease (AD)
Key MechanismsAssociation of retinal layer thickness with plasma biomarkers indicating neurodegeneration and amyloidosis.
Target PopulationCognitively normal adults at increased risk for AD, characterized by low plasma Aβ42/40 ratio.
Care SettingResearch setting, specifically a brain aging cohort.

Key Highlights

  • Thinner inner nuclear layer (INL) and ganglion cell layer (GCL) correlate with higher levels of p-tau217 and GFAP.
  • Study utilized spectral-domain optical coherence tomography (SD-OCT) for retinal measurements.
  • Findings suggest potential for retinal imaging as a complementary tool to plasma biomarkers for early AD risk assessment.
  • Exploratory pilot study with a small sample size (11 participants).
  • Need for larger, longitudinal studies to validate preliminary findings.

Guideline-Based Recommendations

Diagnosis

  • Use of plasma biomarkers such as Aβ42/40, p-tau217, and GFAP for assessing AD risk.

Management

  • Consider retinal imaging as a non-invasive method for monitoring individuals at risk for AD.

Monitoring & Follow-up

  • Regular assessment of plasma biomarkers and retinal layer thickness in at-risk populations.

Risks

  • Potential for misclassification of cognitive status based on plasma biomarker cut-offs.

Patient & Prescribing Data

Cognitively normal adults with a pathological Aβ42/40 ratio indicating increased risk for AD.

Current study does not provide direct treatment recommendations; focuses on risk assessment.

Clinical Best Practices

  • Incorporate retinal imaging in the evaluation of individuals at risk for AD.
  • Utilize a combination of plasma biomarkers and retinal measurements for comprehensive risk assessment.

Related Resources & Content

Original Source(s)

Related Content